BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12710131)

  • 1. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
    Touab M; Arumi-Uría M; Barranco C; Bassols A
    Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Versican overexpression in cutaneous malignant melanoma.
    Gambichler T; Kreuter A; Grothe S; Altmeyer P; Brockmeyer NH; Rotterdam S
    Eur J Med Res; 2008 Nov; 13(11):500-4. PubMed ID: 19073385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
    Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
    Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versican is differentially expressed in human melanoma and may play a role in tumor development.
    Touab M; Villena J; Barranco C; Arumí-Uría M; Bassols A
    Am J Pathol; 2002 Feb; 160(2):549-57. PubMed ID: 11839575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen receptor-beta expression in melanocytic lesions.
    Schmidt AN; Nanney LB; Boyd AS; King LE; Ellis DL
    Exp Dermatol; 2006 Dec; 15(12):971-80. PubMed ID: 17083364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grading of atypia in nevi: correlation with melanoma risk.
    Arumi-Uria M; McNutt NS; Finnerty B
    Mod Pathol; 2003 Aug; 16(8):764-71. PubMed ID: 12920220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma associated with a dysplastic nevus: report of two cases with unusual sebocyte-like melanocytes in the nevus part of the lesion.
    Vazmitel M; Michal M; Mukensnabl P; Kazakov DV
    Am J Dermatopathol; 2007 Dec; 29(6):566-7. PubMed ID: 18032954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
    Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
    Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
    Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
    Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of melanoma precursor lesions.
    Wang Y; Rao U; Mascari R; Richards TJ; Panson AJ; Edington HD; Shipe-Spotloe JM; Donnelly SS; Kirkwood JM; Becker D
    Cell Growth Differ; 1996 Dec; 7(12):1733-40. PubMed ID: 8959342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Focal melanocytic atypia in dysplastic nevus cell nevi. Results of a serial section study].
    Sigg C; Pelloni F; Schnyder UW
    Hautarzt; 1989 Nov; 40(11):701-7. PubMed ID: 2606669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
    Nazarian RM; Prieto VG; Elder DE; Duncan LM
    J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
    Gulyás M; Hjerpe A
    J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micro-anatomy related antigen expression in melanocytic lesions.
    Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
    J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin protein in UVB induced apoptosis of melanoma cells and in melanoma progression.
    Zhang H
    Oncol Rep; 2005 Jun; 13(6):1121-6. PubMed ID: 15870931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hypothesis incorporating the histologic characteristics of dysplastic nevi into the normal biological development of melanocytic nevi.
    Piepkorn M
    Arch Dermatol; 1990 Apr; 126(4):514-8. PubMed ID: 2321996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid leukemia-1 expression in benign and malignant melanocytic lesions.
    Wong RP; Khosravi S; Martinka M; Li G
    Oncol Rep; 2008 Apr; 19(4):933-7. PubMed ID: 18357378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.
    Cohn ML; Goncharuk VN; Diwan AH; Zhang PS; Shen SS; Prieto VG
    J Cutan Pathol; 2005 Sep; 32(8):533-6. PubMed ID: 16115050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.